Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
Pharmaceutical Technology on MSN14h
Alumis and Kaken sign agreement in Japan to develop ESK-001Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...
Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN ...
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...
March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading ...
LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback